Hoofddorp, the Netherlands, 08 December 2022. IGEA Pharma N.V. (SIX: IGPH) today appointed Diego Fiorentini as new CFO of IGEA Pharma, filling a void that was ad interim covered by the previous CEO.
Ad hoc announcement pursuant to article 53 LR
Minutes of the AGM 1 December 2022
Minutes of the Annual General Meeting (the ‘Meeting‘) of IGEA Pharma N.V., a public limited company (naamloze vennootschap), having its registered office in Amsterdam (the Netherlands), and address at: (2132 WT) Hoofddorp, Siriusdreef 17, registered with the Commercial Register of the Chamber of Commerce under number 70212821 (the ‘Company‘), held via (i) Zoom and (ii) in the meeting room next to the Company’s office with address at Hoofddorp Transpolis, Polarisavenue 1, (2123 JH) Hoofddorp (the Netherlands) on 1 December 2022 at 11.00 hours CEST.
IGEA announces annual General Meeting Resolutions
Hoofddorp, the Netherlands, 06 December 2022. IGEA Pharma N.V. (SIX: IGPH) today announced that the Annual General Meeting approved all the agenda resolutions. The minutes of the meeting are available at igeapharma.nl/category/information-for-shareholders
IGEA DISCLOSES ITS HALF-2022 FINANCIAL REPORT
Hoofddorp, the Netherlands, 30 October 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the disclosure of its Half-2022 Financial Report.
Igea discloses its 2021 Annual Report
Hoofddorp, the Netherlands, 20 October 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the disclosure of its 2021 Annual Report.
IGEA to get SIX approval to the semi-annual 2022 report disclosure
Hoofddorp, the Netherlands, 30 September 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the half year 2022 report.
IGEA to get SIX further approval to the 2021 annual report disclosure
Hoofddorp, the Netherlands, 09 August 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
IGEA to get SIX further approval to the 2021 annual report disclosure
Hoofddorp, the Netherlands, 15 July 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.
IGEA Pharma has announced that LMH – an industrial holding company – has completed the due diligence process for a euro 6.000.000 committment to fund the swiss CBD extraction facility
Hoofddorp, the Netherlands, 13th July 2022. Today IGEA Pharma N.V. (SIX: IGPH) has announced that LMH Holding has completed the due diligence process on the Company in relation to its Euro 6.0 million commitment to fund the GMP-Pharma CBD extraction facility owned through its joint-venture Blue Sky Swisse S.A.
IGEA to get SIX further approval to the 2021 annual report disclosure
Hoofddorp, the Netherlands, 15 June 2022. IGEA Pharma N.V. (SIX: IGPH) today announced the grant of a temporary exemption from its disclosure obligations with respect to the 2021 annual report.